Biomodulation of Fluorouracil in Colorectal Cancer

References

• Heidelberger C, Chandhari N K, Douglas H, Jr. Fluorinated pyrimidines. A new class of tumor inhibiting compounds. Nature 1957; 179: 633–666
   PubMedGoogle Scholar
• Poon M A, O'Connell M J, Moertel C G, et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–1418
   PubMed Web of Science ®Google Scholar
• Chu E, Takimoto C H. Anticancer drugs. Principles and Practice of Oncology, V T De Vita, Jr., S Hellman, S A Rosenberg. JB Lippincott, Philadelphia 1993; 358–374
   Google Scholar
• Schuetz J D, Collins J M, Wallace H J, et al. Alteration of the secondary structure of newly synthesized DNA from murine bone marrow cells by 5-fluorouracil. Cancer Res 1986; 46: 119–123
   PubMed Web of Science ®Google Scholar
• Heggie G D, Sommadossi J-P, Cross D S, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987; 47: 2203–2206
   PubMed Web of Science ®Google Scholar
• Mukherjee K L, Boohar J, Wentland D, et al. Studies on fluorinated pyrimidines: XVI. Metabolism of 5-Fluorouracil-2-Ca14 and 5-fluoro-2-deoxyluridine-2-Ca14 in cancer patients. Cancer Res 1963; 23: 49–66
   Web of Science ®Google Scholar
• Coustere C, Mentre F, Sommadossi J P, et al. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother Pharmacol 1991; 28: 123–129
   PubMed Web of Science ®Google Scholar
• McDermott B J, Van der Berg H W, Murphy R F. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol 1982; 9: 173–178
   PubMed Web of Science ®Google Scholar
• Finan P J, Chisholm E M, Giles G R. The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil in patients with colorectal carcinoma. Eur J Surg Oncol 1987; 13: 349–353
   PubMedGoogle Scholar
• Diasio R B, Schuetz J D, Wallas H J, Sommadossi. Dyhydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells. Cancer Res 1985; 45: 4900
   PubMed Web of Science ®Google Scholar
• Grem J. 5-Fluoropyrimidines. Cancer Chemotherapy and Biotherapy, 2nd ed., B Chabner, D Longo. Lippincott-Raven, Philadelphia 1996
   Google Scholar
• Haskell C M, Selch M T, Ramming K P. Colon and rectum. Cancer Treatment, D M Haskell. WB Sanders, Philadelphia 1990; 232–254
   Google Scholar
• Ansfield F, Schreder J M, Currieri A R. Five years experience with 5-fluorouracil. JAMA 1962; 181: 295–299
   PubMed Web of Science ®Google Scholar
• Hryniuk W M, Figueredo A, Goodyear M. Application of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987; 14: 3–11
   PubMed Web of Science ®Google Scholar
• Ansfield F, Klotz J, Nealon T, et al. A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 1977; 39: 34–40
   PubMed Web of Science ®Google Scholar
• Ausman R, Caballero G, Quebbeman E. Long-term ambulatory continuous intravenous infusion of 5-fluorouracil for treatment of advanced adenocarcinomas. Proc Am Soc Clin Oncol 1983; 2: 123, (abstract)
   Google Scholar
• Belt R J, Davidner M L, Myron M C, et al. Continuous low dose 5-fluorouracil (5-FU) for adenocarcinoma: Confirmation of activity. Proc Am Soc Clin Oncol 1985; 4: 90, (abstract)
   Google Scholar
• Benedetto P, Borgos M, Morillo G, et al. Chronic continuous infusion of 5-fluorouracil (CCI-FU) in previously untreated patients (pts) with measurable metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1986; 5: 92, (abstract)
   Google Scholar
• Lokich J J. Colorectal cancer. Cancer Chemotherapy by Infusion, J J Lokich. Precept, Chicago 1987; 291–303
   Google Scholar
• Hansen R, Quebbeman E, Auman, et al. Continuous 5-fluorouracil (5-FU) infusion in colorectal cancer. Update of the MRC experience. Proc Am Soc Clin Oncol 1987; 6: 80, (abstract)
   Google Scholar
• Molina R, Fabian C, Slavik M. Reversal of palmar erythrodysthesia (PPE) by B6 without loss of response in colon cancer patients receiving 200 mg/m2/d continuous 5-FU. Proc Am Soc Clin Oncol 1987; 6: 74, (abstract)
   Google Scholar
• Wade J L, Herbst, Greenburgh A. Prolonged venous infusion (PVI) of 5-fluorouracil (5-FU) for metastatic colon cancer (MCQ-A follow up report. Proc Am Soc Clin Oncol 1988; 7: 94, (abstract)
   Google Scholar
• Schilky R L, Perry M C, Citron M L. High dose 5-fluorouracil (5-FU) therapy for advanced gastrointestinal (GI) malignancy. Proc Am Soc Clin Oncol 1988; 7: 102, (abstract)
   Google Scholar
• Kuo S, Finck S, Cho J, et al. Continuous ambulatory infusional 5-fluorouracil (5-FU) chemotherapy in advanced colorectal cancer: A single institutional retrospective study. Proc Am Soc Clin Oncol 1989; 8: 126, (abstract)
   Google Scholar
• Diaz-Rubio E, Aranda E, Martin M, et al. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 1990; 26: 727–729
   PubMed Web of Science ®Google Scholar
• Rougier P, Ammarguellat H, Ghosn M, et al. Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma. Oncology 1992; 49: 35–39
   PubMed Web of Science ®Google Scholar
• Seifert P, Baker L H, Reed M L, et al. Comparison of continuous infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–128
   PubMed Web of Science ®Google Scholar
• Lokich J J, Ahlgren J D, Gullo J J, et al. A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–432
   PubMed Web of Science ®Google Scholar
• Weinemann B, Shah A, Fields A, et al. A randomized trial of continuous systemic infusion (CSI) vs. bolus therapy (B) with 5-fluorouracil (5FU) in metastatic measurable colorectal cancer (MCC). Am J Clin Oncol 1992; 15: 518–523, (abstract)
   PubMedGoogle Scholar
• Lokich J J, Moore C. Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798–800
   PubMed Web of Science ®Google Scholar
• Fiskus J. The effect of two methods of delivery of 5-fluorouracil on quality of life. Oncol Nurs Forum 1987; 14(Suppl 2)122
   Google Scholar
• Leichman C G, Fleming T R, Muggia F M, et al. Phase II study of fluorouracil (5-FU) and its modulation in advanced colorectal cancer: A Southwest Oncology Group (SWOG) study. J Clin Oncol 1995; 13: 1303–1311
   PubMed Web of Science ®Google Scholar
• O'Dwyer P J, Ryan L M, Valone J D, et al. Phase III trial of biochemical modulation of 5-FU by IV or oral leucovorin or by interferon in advanced colorectal cancer: An ECOG/CALGB phase III trial. Proc Am Soc Clin Oncol 1996; 15: 207, (abstract)
   Google Scholar
• Baccanari D P, Davis S, Knick V C, et al. 5-Ethynyluracil: A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993; 90: 11064–11068
   PubMed Web of Science ®Google Scholar
• Cao S, Rustum Y M, Spector T. 5-Ethynyluracil (776C85): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994; 54: 1507–1510
   PubMed Web of Science ®Google Scholar
• Spector T, Cao S, Rustum Y M, et al. Attenuation of the antitumor activity of 5-fluorouracil by R-5-fluoro-5,6-dihydrouracil. Cancer Res 1995; 55: 1239–1241
   PubMed Web of Science ®Google Scholar
• Kemeny N. Role of chemotherapy in the treatment of colorectal carcinoma. Semin Surg Oncol 1987; 3: 190–214
   PubMed Web of Science ®Google Scholar
• Bruckner H, Cohen J. MTX/5-FU trials in gastrointestinal and other cancers. Semin Oncol 1983; 10: 32–39
   PubMed Web of Science ®Google Scholar
• Marsh J C, Bertino J R, Rome L S, et al. Sequential methotrexate, 5-fluorouracil and leucovorin in metastatic colorectal cancer: A controlled comparison of two intervals between drug administration. Proc Am Soc Clin Oncol 1989; 8: 103, (abstract)
   Web of Science ®Google Scholar
• Cadman E, Heimer R, Benz C. The influence of methotrexate pretreatment of 5-fluorouracil metabolism in L1210 cells. J Biol Chem 1981; 256: 1695–1704
   PubMed Web of Science ®Google Scholar
• Cadman E, Davis L, Heimer R. Enhanced 5-fluorouracil nucleotide formation following methotrexate: Biochemical explanation for drug synergism. Science 1979; 205: 1135
   PubMed Web of Science ®Google Scholar
• Allegra C J, Chabner B A, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1986; 230: 9720
   Google Scholar
• Bertino J R, Mini E, Fernandes D J. Sequential methotrexate and 5-fluorouracil: Mechanisms of synergy. Semin Oncol 1983; 10(Suppl 2)2
   PubMed Web of Science ®Google Scholar
• Benz C, Tillis T, Tattelman E, Cadman E. Optimal scheduling of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 1982; 42: 2081
   PubMed Web of Science ®Google Scholar
• Benz C, Schoenberg M, Choti M. Schedule dependent cytotoxicity of methotrexate and 5-FU in human colon and breast tumor cells. J Clin Invest 1980; 66: 1162–1165
   PubMed Web of Science ®Google Scholar
• Bertino J R, Sawixki W L, Lindquist C A, et al. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 1977; 37: 327–328
   PubMed Web of Science ®Google Scholar
• Mini E, Bertino J R. Time and dose relationships for methotrexate, fluorouracil and combinations of these drugs for maximum cell kill in human CCRF-CEM cells. Proc Am Assoc Cancer Res 1982; 23: 181, (abstract)
   Web of Science ®Google Scholar
• El-Tahtawy A, Wolf W. In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-FU, using 19sF nuclear magnetic resonance spectroscopy. Cancer Res 1991; 51: 5806
   PubMed Web of Science ®Google Scholar
• Sawyer R C, Stolfi R L, Martin D S, Balis M E. Inhibition by methotrexate of the stable incorporation of 5-FU into murine bone marrow DNA. Biochem Pharmacol 1989; 38: 2305
   PubMed Web of Science ®Google Scholar
• McSheehy P MJ, Prior M J, Griffiths J R. Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat walker carcinosarcoma following methotrexate pre-treatment: A F-MRS study in vivo. Br J Cancer 1992; 65: 369
   PubMed Web of Science ®Google Scholar
• Marsh J C, Bertino J R, Katz K H, et al. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 1991; 9: 371
   PubMed Web of Science ®Google Scholar
• Plotkin D, Ray M, Chien P. Sequential mefhotrexate-5-fluo-rouracil in advanced breast and colorectal cancer: A non-randomized pilot study. Proc Am Soc Clin Oncol 1988; 7: 25, (abstract)
   Google Scholar
• De Marco L C, Arena F, Desner M, et al. Low dose leucovorin and 5-FU modulation with prior methotrexate (L-FUSE-ME) for metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 1988; 7: 104, (abstract)
   Google Scholar
• Sierra R, Colman L, White D, et al. Sequential therapy with methotrexate and infusional 5-FU in advanced colorectal cancer. Proc Am Soc Clin Oncol 1988; 7: 105, (abstract)
   Google Scholar
• Heim M E, Schuster D, Fletchtner H, et al. Sequential high-dose methotrexate. 5-fluorouracil and folinic does not improve responses in advanced colorectal cancer. Onkologie 1989; 12: 161–163
   PubMed Web of Science ®Google Scholar
• Richards F, II, Capizi R L, Muss H, et al. 5-fluorouracil (5-FU), high dose folinic acid and methotrexate for advanced colorectal cancer. A phase II trial of the Piedmont Oncology Association. Proc Am Soc Clin Oncol 1989; 8: 101, (abstract)
   Google Scholar
• Ajani J A, Kanojia M D, Bedikian A V. High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. Am J Clin Oncol 1989; 12: 335–338
   PubMed Web of Science ®Google Scholar
• Balaban E, Frenkel E, Periman P, et al. Sequential methotrexate, high-dose folinic acid, and 5-fluorouracil for advanced colorectal carcinoma: A phase II trial of the Texas Regional Oncology Group. Proc Am Soc Clin Oncol 1990; 9: 122, (abstract)
   Google Scholar
• The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial. J Clin Oncol 1989; 7: 1437–1446
   PubMed Web of Science ®Google Scholar
• Valone F H, Friedman M A, Wittlinger P S, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7: 1427–1436
   PubMed Web of Science ®Google Scholar
• Macchiavelli M, Leone B A, Romero A, et al. Advanced colorectal carcinoma (CRC): A prospective randomized trial of sequential methotrexate (MTX)-5-fluorouracil (5-FU) vs. 5-FU alone. Proc Am Soc Clin Oncol 1990; 9: 102, (abstract)
   Google Scholar
• Kemeny N, Reichman B, Geller N, et al. Implementation of the group sequential methodology in a randomized trial in metastatic colorectal carcinoma. Am J Clin Oncol 1988; 11: 66–72
   PubMed Web of Science ®Google Scholar
• Hermann R, Knuth A, Kleeberg U, et al. Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society. Ann Oncol 1992; 3: 539–543
   PubMed Web of Science ®Google Scholar
• O'Connell M J, Poon M A, Wieand H S. Biochemical modulation of 5-fluorouracil (5-FU) with leucovorin (LV): Confirmatory evidence of improved therapeutic efficacy in the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 1990; 9: A408, (abstract)
   Google Scholar
• Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559–1565
   PubMed Web of Science ®Google Scholar
• Polyzos A, Tsavaris N, Giannopoulous A, et al. Biochemical modulation of fluorouracil: Comparison of methotrexate, folinic acid and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. Cancer Chemother Pharmacol 1996; 38: 292–297
   PubMed Web of Science ®Google Scholar
• O'Dwyer P J, DeLap R J, et al. Trimetrexate: Clinical development of a nonclassical antifolate. Natl Cancer Inst Monogr 1987; 5: 105–109
   Google Scholar
• Kamen B A, Cashmore A R, Dreyers R N, et al. Uptake and efficacy of trimetrexate, a nonclassical antifolate in methotrexate resistant leukemia cells in vitro. Biochem Pharmacol 1984; 33: 1697–1699
   PubMed Web of Science ®Google Scholar
• Jackson R C, Froy D W, et al. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul 1984; 22: 187–206
   PubMedGoogle Scholar
• Romanini A, Li W W, Colofiore J R, Bertino J R. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J Natl Cancer Inst 1992; 84: 1033–1038
   PubMed Web of Science ®Google Scholar
• Conti J A, Kemeny N, Seiter K, et al. Trial of sequential trimetrexate, fluorouracil and high dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994; 12: 695–700
   PubMed Web of Science ®Google Scholar
• Blanke C, Kasimis B, Schein P. A phase II trial of trimetrexate, 5-fluorouracil and leucovorin in patients with unresectable or metastatic colon cancer. Proc Am Soc Clin Oncol 1996; 15: 433, (abstract)
   Google Scholar
• Silgals R M, Ahlgren J D, Neefe J R, et al. A phase II trial of high dose intravenous interferon alpha 2 in advanced colorectal cancer. Cancer 1984; 54: 2257–2261
   PubMed Web of Science ®Google Scholar
• Krown S E, Mintzer D, Cunningham-Rundles S, et al. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: Clinical results and modification of biological responses. Cancer Treat Rep. 1987; 71: 39–45
   PubMedGoogle Scholar
• Lillis P K, Brown T, Beougher K, et al. A phase II trial of recombinant beta interferon (Betaseron) in advanced colorectal cancer. Proc Am Soc Clin Oncol. 1987; 6: 86, (abstract)
   Google Scholar
• Brown T, Fleming T, Goodman P, Macdonald J. Randomized phase II trial of recombinant gamma interferon administered on two schedules in advanced colorectal cancer: A Southwest Oncology Group trial. Proc Am Soc Clin Oncol. 1989; 8: 124, (abstract)
   Google Scholar
• Elias L, Crissman H A. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 1988; 48: 4868–4873
   PubMed Web of Science ®Google Scholar
• Wadler S, Schwartz E L, Goldman M, et al. Preclinical and clinical studies of 5-fluorouracil and recombinant alpha-2a-interferon against gastrointestinal malignancies. Clin Res 1988; 36: 803A, (abstract)
   Google Scholar
• Namba M, Myoshi T, Kanamori T, et al. Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture. Gann 1982; 73: 819–824
   PubMedGoogle Scholar
• Welander C E, Morgan T M, Homesly H D, et al. Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 1985; 35: 721–729
   PubMed Web of Science ®Google Scholar
• Chu E, Sinn S, Boarman D, et al. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990; 50: 5834–5840
   PubMed Web of Science ®Google Scholar
• Pazdur R. Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms. Br J Hematol 1991; 79(Suppl 1)56–59
   PubMedGoogle Scholar
• Wadler S, Lembersky B, Kirkwood J, et al. Phase II trial of fluorouracil (5FU) and recombinant alpha-2 interferon (IFN) in patients (pts) with advanced colorectal cancer: An Eastern Cooperative Oncology Group (ECOG) study. J Clin Oncol 1991; 9: 1806–1810
   PubMed Web of Science ®Google Scholar
• Grem J, McAtee N, Murphy R F, et al. Phase I study of interferon alpha-2a (INF-A), in combination with 5-fluorouracil (5-FU) and high dose leucovorin (LV) in metastatic gastrointestinal carcinoma. J Clin Oncol 1991; 9: 1811
   PubMed Web of Science ®Google Scholar
• Wadler S, Wiemik P H. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17: 16–21
   PubMed Web of Science ®Google Scholar
• Kemeny N E, Schneider A, Martin D S. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity. Cancer Invest 1990; 8: 263–264
   PubMedGoogle Scholar
• Einhom S, Blomgren H, Strander H. Interferon and spontaneous cytotoxicity in man. Acta Med Scand 1978; 204: 477–483
   PubMed Web of Science ®Google Scholar
• Hunddlestone J R, Merigan T O, Okistone M BA. Induction and kinetics of natural killers in humans following interferon therapy. Nature 1979; 282: 417–419
   PubMed Web of Science ®Google Scholar
• Gewert D R, Moore, Clemens M J. Inhibition of cell division by interferons. The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cells. Biochem J 1983; 214: 983–990
   PubMed Web of Science ®Google Scholar
• Kase S, Kubota T, Watanabe M, et al. Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating flu-orouridine concentration in tumor tissue. Anticancer Res 1994; 14(3A)1155–1159
   PubMed Web of Science ®Google Scholar
• Wadler S, Goldman M, Lyver A, et al. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma. Cancer Res 1990; 50: 2056–2059
   PubMed Web of Science ®Google Scholar
• Wadler S, Schwartz E L, Godman M, et al. Fluorouracil and recombinant aIpha-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–1775
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Nicolaides C, Athanassiadis A, et al. Phase II study of 5-fluorouracil and interferon gamma in patients with metastatic colorectal cancer. A Hellenic Cooperative Oncology Group Study. Oncology 1996; 53: 159–162
   PubMed Web of Science ®Google Scholar
• Pazdur R, Ajani J A, Patt Y Z, et al. Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990; 8: 2027–2031
   PubMed Web of Science ®Google Scholar
• Fomasiero A, Daniele O, Ghiotto C, et al. Alpha 2 interferon and 5-fluorouracil in advanced colorectal cancer. Tumori 1990; 76: 385–388
   PubMed Web of Science ®Google Scholar
• Huberman M, McClay E, Atkins M, et al. Phase II trial of 5 fluorouracil (5FU) and recombinant interferon-alpha-2a (INF) in advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 153, (abstract)
   Google Scholar
• Douillard J, Leborgne Y. J, Danielou J Y, et al. Phase II trial of 5-fluorouracil (5FU) and recombinant alpha interferon (RAIFN) (Intron AR) in metastatic, previously untreated colorectal cancer (CRC). Proc Am Soc Clin Oncol 1991; 10: 139, (abstract)
   Google Scholar
• Pazdur Ajani JA, Patt Y Z, et al. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. Cancer 1993; 71: 1214–1218
   PubMed Web of Science ®Google Scholar
• Pazdur R, Abbruzzese J, Faintuch J, et al. Phase II study of recombinant interferon alpha and 5-fluorouracil in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1990; 9: 117, (abstract)
   Google Scholar
• Huberman M, Bering H, Tessitore J, et al. 5-fluorouracil plus recombinant alpha interferon (Roferon A) in advanced colorectal cancer. Proc Am Soc Clin Oncol 1990; 9: 116, (abstract)
   Google Scholar
• Kemeny N, Kelsen D, Derby S, et al. Combination of 5-fluorouracil plus recombinant alpha interferon in advanced colorectal cancer. Proc Am Soc Clin Oncol 1990; 9: 109
   Google Scholar
• Kocha W. The Corfu-A Collaborative Group: 5-Fluorouracil (5-FU) plus interferon alfa-2a (Roferon-A) versus 5-fluorouracil plus leucovorin (LV) in metastatic colorectal cancer-Results of a multicenter multinational phase III study. Proc Am Soc Clin Oncol 1993; 12: 193, (abstract)
   Google Scholar
• Hill M, Norman A, Cunningham D, et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995; 13: 1297–1302
   PubMed Web of Science ®Google Scholar
• York M, Greco F A, Figlin R A, et al. A randomized phase III trial comparing 5-FU with or without interferon alfa 2a for advanced colorectal cancer. Proc Am Soc Clin Oncol 1993; 12: 200, (abstract)
   Google Scholar
• Kreuser E D, Matthias M, Boewer C, et al. Double modulation of 5-fluorouracil with interferon a-2b and folinic acid in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 150, (abstract)
   Google Scholar
• Labianca R, Pancera G, Luporini A, et al. Double modulation of 5-fluorouracil (5FU) with a2b interferon (IFN) and folinic acid (FA) in advanced colorectal cancer. Ann Oncol 1990; 1(Suppl)92
   Google Scholar
• Punt C JA, De Mulder P HM, Burghouts J TM. A phase I-II study of high dose 5-fluorouracil (5FU), leucovorin (LV) and a-inter-feron (aINF) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 150, (abstract)
   Google Scholar
• Inoshita G, Yalavarthi P, Murthy S, et al. Phase I trial of 5FU, leucovorin (LV) and rHuINF-a2a in metastatic colorectal cancer (CR Ca). Proc Am Soc Clin Oncol 1991; 10: 152, (abstract)
   Google Scholar
• Kohne-Wompner C H, Schmoll H J, Hiddemann H, et al. 5-fluorouracil (FU), leucovorin (LV), alpha-2b interferon (INF) in advanced colorectal cancer (CC): A phase I/II study. Proc Am Soc Clin Oncol 1991; 10: 159, (abstract)
   Google Scholar
• Schuller J, Czejka M, Miksche M. Influence of interferon a 2b (IFN) leucovorin (LV) on pharmacokinetics (PK) of 5-fluorouracil. Proc Am Soc Clin Oncol 1991; 10: 98, (abstract)
   Google Scholar
• Grem J L, Jordan E, Robson M E, Binder R A, et al. Phase II study of fluorouracil, leucovorin and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 1993; 11: 1737–1745
   PubMed Web of Science ®Google Scholar
• Sinnigie H A. Phase I-II study of the addition of alpha-2a interferon to 5-FU leucovorin-pharmacokinetic interaction of alpha-2A interferon and leucovorin. Eur J Cancer 1993; 29A: 1715–1720
   PubMed Web of Science ®Google Scholar
• Mini E, Moroson B A, Bertino J R. Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymiphoblast leukemia cells: Enhancement by leucovorin. Cancer Treat Rep 1987; 71: 381–389
   PubMedGoogle Scholar
• Grem J. 5-Fluoropyrimidines. Cancer Chemotherapy and Biotherapy, 2nd ed, B Chabner, D Longo. Lippincot-Raven, Philadelphia 1996
   Google Scholar
• Houghton J A, Williams L G, Siebold S N, et al. Relationship between dose rate of [6RS] leucovorin administration, plasma concentrations of reduced folates, and pools of 5, 10-methylene-tetrahydrofolate and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 1990; 50: 3493–3502
   PubMed Web of Science ®Google Scholar
• Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986; 4: 685–696
   PubMed Web of Science ®Google Scholar
• Laufman L R, Krzeczowski K, Roach R, et al. Leucovorin plus 5-fluorouracil: An effective treatment for metastatic colon cancer. J Clin Oncol 1987; 5: 1394–1400
   PubMed Web of Science ®Google Scholar
• DeGramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988; 24: 1499–1503
   PubMedGoogle Scholar
• Di Costanzo F, Bartolucci R, Padalino D, et al. High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. Cancer Invest 1988; 6: 133–138
   PubMed Web of Science ®Google Scholar
• Laufman L R, Brenckman W DJ, Stydnicki K A, et al. Clinical experience with leucovorin and 5-fluorouracil. Cancer 1989; 63: 1031–1035
   PubMed Web of Science ®Google Scholar
• Fried G, Tsalk M, Stein M, et al. 5-Fluorouracil and low dose leucovorin in metastatic colorectal cancer. A pilot study. Cancer Chemother Pharmacol 1995; 35: 437–440
   PubMed Web of Science ®Google Scholar
• Abad A, Garcia P, Gravalos C, et al. Sequential methotrexate, 5-fluorouracil and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multiinstitutional randomized trial. Cancer 1995; 75: 1238–1244
   PubMed Web of Science ®Google Scholar
• Erlichman C, Fine S, Kerr I, et al. A phase II trial of 5-FU and 1-leucovorin in patients with metastatic colorectal cancer. Am J Clin Oncol 1996; 19: 26–31
   PubMed Web of Science ®Google Scholar
• Recchia F, Nuzzo A, Calli A, et al. Randomized trial of 5-FU and high dose folinic acid with or without alpha-215 interferon in advanced colorectal cancer. Am J Clin Oncol 1996; 19(3)301–304
   PubMed Web of Science ®Google Scholar
• Advanced Colorectal Meta-Analysis project. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903
   PubMed Web of Science ®Google Scholar
• Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469–475
   PubMed Web of Science ®Google Scholar
• Labianca R, Pancera G. A randomized study of intravenous fluorouracil + folinic acid (FA) in advanced metastatic colorectal cancer (AMC). Proc Am Soc Clin Oncol 1989; 8: 118, (abstract)
   Google Scholar
• Petrelli N, Douglass H OJ, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gatrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419–1426
   PubMed Web of Science ®Google Scholar
• Doroshow J H, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491–501
   PubMed Web of Science ®Google Scholar
• Brenckman W D, Laufman L R, Adamkiewicz M A, et al. Is fluorouracil (FU) plus placebo (P) as effective as equitoxic doses of FU plus high dose oral leucovorin (LV) in colorectal cancer?. Proc Am Soc Clin Oncol 1990; 9: 109, (abstract)
   Google Scholar
• Di Costanzo F, Bartolucci R, Calabresi F, et al. Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1992; 3: 371–376
   PubMed Web of Science ®Google Scholar
• Loftier T M, Korsten F W, Reis H E, et al. Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma. Dtsch Med Wochenschr 1992; 117: 1007–1013
   PubMed Web of Science ®Google Scholar
• Nobile M T, Rosso R, Sertoli M R, et al. Randomized comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 1992; 28A: 1823–1827
   PubMed Web of Science ®Google Scholar
• Steinke B, Gunther E, Hirschmann W D, et al. Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer-preliminary results of a randomized trial. Semin Oncol 1992; 19(2 Suppl 3)141–147
   PubMed Web of Science ®Google Scholar
• Poon M A, O'Connel M J, Vieand H S, et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967
   PubMed Web of Science ®Google Scholar
• Houghton P J, Rahman A, Will C L, et al. Mutation of the thymidy late synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates. Cancer Res 1992; 52: 558
   PubMed Web of Science ®Google Scholar
• Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 1988; 6: 1053–1058
   PubMed Web of Science ®Google Scholar
• Ardalan B, Chua L, Er-Ming T, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625–630
   PubMed Web of Science ®Google Scholar
• Ardalan B, Hussein A, Skaver L, et al. Chemotherapy (C) of advanced carcinoma (CA) with 5-fluorouracil (FU) with leucovorin (LV). Proc Am Soc Clin Oncol 1989; 8: 116, (abstract)
   Google Scholar
• Ardalan B, Glazer R I, Kensler T W, et al. Synergistic effect of fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in a human mammary carcinoma. Biochem Pharmacol 1981; 30: 2045–2049
   PubMed Web of Science ®Google Scholar
• Spiegelman S, Sawyer R R, Naya R, et al. Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA metabolic modulation. Proc Natl Acad Sci USA 1980; 77: 4966–4970
   PubMed Web of Science ®Google Scholar
• Martin D S, Stolfi R L, Sawyer R C, et al. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance. Cancer Res 1983; 43: 2317–2321
   PubMed Web of Science ®Google Scholar
• Ardalan B, Villacorte D, Heck D, Corbett T. Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinoma. Biochem Pharmacol 1982; 31: 1989–1992
   PubMed Web of Science ®Google Scholar
• Chi-Ming L, Donehower C, Chabner B. Biochemical interactions between N-(phosphonacetyl)-L aspartate and 5-fluorouracil. Mol Pharmacol 1982; 21: 224–230
   PubMed Web of Science ®Google Scholar
• Bedikian A Y, Stroehlein J R, Karlin D A, et al. Chemotherapy for colorectal cancer with a combination of PALA and 5-FU. Cancer Treat Rep 1981; 65: 747–753
   PubMedGoogle Scholar
• O'Connell M J, Powis G, Rubin J, et al. Pilot study of PALA and 5-FU in patients with advanced cancer. Cancer Treat Rep 1981; 66: 331–334
   Google Scholar
• Martin D S, Stolfi R L, Sawyer R C, et al. Application of biochem ical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy. Cancer Treat Rep 1985; 69: 421–423
   PubMedGoogle Scholar
• Muggia F M, Camacho F J, Kaplan B H, et al. Weekly 5-fluorouracil combined with PALA: Toxic and therapeutic effects in colorectal cancer. Cancer Treat Rep 1987; 71: 253–256
   PubMedGoogle Scholar
• Buroker T R, Moerte C G, Fleming T R, et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 1985; 3: 1624–1631
   PubMed Web of Science ®Google Scholar
• Grem J L, King S A, O'Dwyer P J, Leyland-Jones B. Biochemistry and clinical activity of PALA: A review. Cancer Res 1988; 48: 4441–4454
   PubMed Web of Science ®Google Scholar
• Casper E S, Vale K, Williams L J, et al. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. Cancer Res 1983; 43: 2324–2329
   PubMed Web of Science ®Google Scholar
• O'Dwyer P J, Paul A R, Walczak J, et al. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 1988; 6: 1053–1058
   PubMedGoogle Scholar
• Ardalan B, Sridhar K S, Benedetto P, et al. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer 1991; 68: 1242–1246
   PubMed Web of Science ®Google Scholar
• Martin D S (1987) Biochemical modulation: perspectives and objectives. Proceedings of the Eighth Bristol-Myers Symposium on Cancer Research. New Avenues in Developmental Cancer Chemotherapy. 1987, K R Harrap, T A Connors. Academic Press, London, 113–162
   Google Scholar